102. Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7.Adjuvant endocrine therapy in premenopausal patients with hormonereceptor-positive early breast cancer: Evidence evaluation and GRADErecommendations by the Italian Association of Medical Oncology (AIOM).Gori S(1), Puglisi F(2), Cinquini M(3), Pappagallo G(4), Frassoldati A(5),Biganzoli L(6), Cortesi L(7), Fiorentino A(8), Angiolini C(9), Tinterri C(10), DeCensi A(11), Levaggi A(12), Del Mastro L(13).Author information: (1)Medical Oncology Unit, Sacro Cuore - Don Calabria Hospital, Cancer CareCenter, Via Don Angelo Sempreboni 5, 37024 Negrar, VR, Italy. Electronic address:stefania.gori@sacrocuore.it.(2)Struttura Operativa Complessa "Oncologia Medica e Prevenzione Oncologica",Dipartimento di Oncologia Clinica, Centro di Riferimento Oncologico IstitutoNazionale Tumori, Aviano, PN, Italy; Dipartimento Area Medica, Università degliStudi di Udine, Italy. Electronic address: fabio.puglisi@uniud.it.(3)IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Oncology Department,Via Giuseppe La Masa 19, 20156 Milan, Italy. Electronic address:michela.cinquini@marionegri.it.(4)Epidemiology & Clinical Trials Office, General Hospital, Via Don GiacobbeSartor 4, 30035 Mirano, VE, Italy. Electronic address:giovanni.pappagallo@gmail.com.(5)Clinical Oncology, Arcispedale Sant'Anna University Hospital, Via Aldo Moro 8,44124 Ferrara, Italy. Electronic address: a.frassoldati@ospfe.it.(6)Medical Oncology Department, Hospital of Prato, P.zza Dell'Ospedale 2, 59100Prato, Italy. Electronic address: lbiganzoli@uslcentro.toscana.it.(7)Department of Oncology and Hematology, University Hospital of Modena andReggio Emilia, Via Del Pozzo 71, 41100 Modena, Italy. Electronic address:hbc@unimore.it.(8)Radiation Oncology Division, Sacro Cuore - Don Calabria Hospital, Cancer Care Center, Via Don Angelo Sempreboni 5, 37024 Negrar, VR, Italy. Electronic address:alba.fiorentino@sacrocuore.it.(9)SOD Oncologia Della Mammella- Breast Unit-DAI Oncologico-Azienda Ospedaliero- Universitaria Careggi, Largo Brambilla 3, 50134 Firenze, Italy. Electronicaddress: angiolinic@aou-careggi.toscana.it.(10)Department of Surgery, IRCCS Clinical and Research Institute Humanitas, ViaManzoni 56, 20089 Rozzano, MI, Italy. Electronic address:corrado.tinterri@cancercenter.humanitas.it.(11)Medical Oncology Unit, Galliera Hospital, Via Alessandro Volta 8, 16128Genova, Italy. Electronic address: andrea.decensi@galliera.it.(12)Department of Oncology, Sant'Andrea Hospital, Via Vittorio Veneto 197, 19121 La Spezia, Italy. Electronic address: ale.levaggi@gmail.com.(13)Department of Medical Oncology, U.O. Sviluppo Terapie Innovative, IRCCS AOUSan Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, Italy. Electronic address: lucia.delmastro@hsanmartino.it.Premenopausal women with hormone receptor-positive early breast cancer arecandidates for adjuvant endocrine therapy, as recommended by the majorinternational guidelines. To date, adjuvant endocrine options for premenopausalwomen include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment ofpremenopausal women with hormone-responsive breast cancer have been assessed, andthe results of randomised clinical trials have been reported over the last years.Despite this evidence, the optimal algorithm for endocrine therapy forpremenopausal women with hormone receptor-positive early stage invasive breastcancer shows open questions regarding the role of OFS in addition to tamoxifenand the optimal use of hormonal agents. The panel of the Italian Association ofMedical Oncology (AIOM) Clinical Practice Guidelines on Breast Cancer applied theGrades of Recommendation, Assessment, Development and Evaluation (GRADE)methodology on three critical questions on the choice of the adjuvant hormonaltherapy in premenopausal breast cancer patients to summarise available evidenceand to create recommendations to help physicians in their clinical practice.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.04.006 PMID: 29886394 